Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Fig. 2

Comparison of pegloticase exposure with methotrexate co-treatment in the current study (MIRROR OL) and as monotherapy in prior phase 3 trials. Blue circles represent responders, and red circles represent non-responders. The gray dotted line shows the limit of quantitation (LOQ) of pegloticase measurements (0.6 µg/mL). Data below LOQ (BQL) were imputed as 0.3 µg/mL

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us